Catalyst Wire Dossier Catalyst Wire Dossier

Soquelitinib

· Corvus Pharmaceuticals, Inc.
Drug timelines are a Plus or Pro feature.

4 regulatory and trial events tracked for Soquelitinib, covering 2026-03-05 to 2026-04-16. Get the full timeline:

Most recent: Clinical Trial Update: Study of the ITK Inhibitor Soquelitinib to Reduce Lymphoproliferation and Improve Cytopenias in Autoimmune Lymphoproliferative Syndrome (ALPS)-FAS Patients [Phase 2]

See pricing